Luke Nauth is an associate in the London office of Latham & Watkins and a member of the firm's Healthcare & Life Sciences Practice.

Luke advises multinational companies and startups in the pharmaceutical, biotech, and medical devices sectors, as well as their investors on a broad variety of complex EU, UK, and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations, and general compliance matters.

Luke also advises on licensing and collaboration agreements, manufacturing and services agreements, and clinical trial agreements. 

Luke is a qualified pharmacist in Great Britain. Prior to joining Latham, he was an associate in the Life Sciences group at a global law firm, and completed a secondment at Ellipses Pharma Limited. He has also worked in the regulatory, technical, and legal affairs department at Essential Pharma Limited, and completed an internship at Roche Products Limited. 

Luke is a member of the Royal Pharmaceutical Society and The Organisation for Professionals in Regulatory Affairs. He is also a professional ambassador for Aspiring Solicitors, providing support for diverse candidates pursuing a career in law.

Luke’s experience includes advising: 

  • Biocon Biologics on its acquisition of Viatris’ biosimilar business*
  • Medical Properties Trust on its acquisition of Hospital Portfolio*
  • Vaccitech on its initial public offering*
  • MBX Biosciences on its initial public offering*
  • Q32 Bio on its merger with Homology Medicines*
  • Alkermes on the separation of its oncology business*
  • Behrman Capital on its acquisition of Orphan Reach*

*Matter handled prior joining to Latham

Bar Qualification

  • England and Wales (Solicitor)

Education

  • LPC, The University of Law, 2016
  • Graduate Diploma in Law, The University of Law, 2015
  • Master of Pharmacy, King's College London, 2013

Languages Spoken

  • English